YMDD variants to HBV DNA polymerase gene: Rapid detection and clinicopathological analysis with long-term lamivudine therapy after liver transplantation

World Journal of Gastroenterology

Volumn 11, Issue 18, 2005, Pages 2714-2719

  Pei, Fei ^a   Ning, Jun Yu ^a   You, Jiang Feng ^a   Yang, Jing Pin ^a   Zheng, Jie ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

HBV DNA; Liver transplantation; PCR RFLP; Polymerase gene; YMDD variants

Indexed keywords

DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LIVER ENZYME; VIRUS DNA;

ACCURACY; ADULT; ARTICLE; CAUSE OF DEATH; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; FATALITY; GASTROINTESTINAL HEMORRHAGE; GENETIC VARIABILITY; GENOTYPE; GRAFT REJECTION; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOLOGY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; LONG TERM CARE; MALE; METHODOLOGY; NONHUMAN; PATHOLOGY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; STRUCTURAL GENE; TREATMENT WITHDRAWAL; WILD TYPE;

EID: 18944387675     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i18.2714     Document Type: Article

References (32)

1. Hanazaki K. Antiviral therapy for chronic hepatitis B: a review. Curr Drug Targets Inflamm Allergy 2004; 3: 63-70
2. Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: have we learned from our results? Hepatology 1991; 13: 796-799
3. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effects of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Inter Med 1993; 119: 312-323
4. Fu L, Liu SH, Cheng YC. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues. Biochem Pharmacol 1999; 15: 1351-1359
5. Ling R, Mutimer D, Ahmed M, Boxall Eh, Elias E, Du-sheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 3: 711-713
6. Nevens F, Main J, Honkoop P, Tyrrell Dl, Braber J, Sullivan M, Fevery J, De-Man RA, Thomas HC. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose ranging study. Gastroenterology 1997; 113: 1258-1263
7. Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR, Wong J, Lai EC, Sung JJ. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant 2004; 18: 295-300
8. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, Wong DK, Sum SM, Ng IO, Fan ST, Lai CL. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003; 39: 850-855
9. Beckebaum S, Cicinnati VR, Gerken G, Broelsch CE. Treatment of hepatitis B reinfection after liver transplantation. Minerva Chir 2003; 58: 705-716
10. Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation 1999; 68: 232-236
11. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81-90
12. Lagget M, Rizzetto M. Current pharmacotherapy for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2003; 4: 1821-1827
13. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, Seong BL, Kim SI, Han KH. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol 2003; 71: 367-375
14. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Gardner SD, Brown N, Griffiths D. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl 2003; 9: 49-56
15. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003; 98: 151-159
16. Perrillo RP. How will we use the new antiviral agents for hepatitis B? Curr Gastroenterol Rep 2002; 4: 63-71
17. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, Trautwein C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264-273
18. Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998: 1711-1716
19. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714-717
20. Sokal E. Lamivudine for the treatment of chronic hepatitis B. Expert Opin Pharmacother 2002; 3: 329-339
21. Shapira R, Daudi N, Klein A, Shouval D, Mor E, Tur-Kaspa R, Dinari G, Ben-Ari Z. Seroconversion after the addition of famciclovir therapy in a child with hepatitis B virus infection after liver transplantation who developed lamivudine resistance. Transplantation 2002; 73: 820-822
22. Lagget M, Rizzetto M. Treatment of chronic hepatitis B. Curr Pharm Des 2002; 8: 953-958
23. Benhamou Y, Dohin E, Lunel-Fabiani F, Poynard T, Huraux JM, Katlama C, Opolon P, Gentilini M. Efficacy of lamivudine on replication of hepatitis B virus in HIV - infected patients. Lancet 1995; 345: 396-397
24. Pramoolsinsup C. Management of viral hepatitis B. Gastroenterol Hepatol 2002; 17(Suppl): S125-145
25. Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ. Factors associated with viral break-through in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182-187
26. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, Neuhaus R, Berg T, Neuhaus P. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 2002; 40: 795-799
27. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002
28. Villamil FG, Hepatitis B. progress in the last 15 years. Liver Transpl 2002; 8(10 Suppl 1): S59-66
29. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-117
30. Fontana RJ, Hann HW, Wright T, Everson G, Baker A, Schiff ER, Riely C, Anschuetz G, Riker-Hopkins M, Brown N. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-510
31. Seta T, Yokosuka O, Imazeki F, Tagawa M, Saisho, H. Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J Med Virol 2000; 60: 8-16
32. Jardi R, Buti M, Rodriguez-Frias F, Cotrina M, Costa X, Pascual C, Esteban R, Guardia J. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J Virol Met 1999; 83: 181-187